| Literature DB >> 29410733 |
Lucian Hritcu1, Radu Ionita1, Paula Alexandra Postu1, Girish Kumar Gupta2, Hasan Turkez3, Tamires Cardoso Lima4, Caroline Uchôa Souza Carvalho5, Damião Pergentino de Sousa5.
Abstract
Depression is a serious disorder that affects hundreds of millions of people around the world and causes poor quality of life, problem behaviors, and limitations in activities of daily living. Therefore, the search for new therapeutic options is of high interest and growth. Research on the relationship between depression and oxidative stress has shown important biochemical aspects in the development of this disease. Flavonoids are a class of natural products that exhibit several pharmacological properties, including antidepressant-like activity, and affects various physiological and biochemical functions in the body. Studies show the clinical potential of antioxidant flavonoids in treating depressive disorders and strongly suggest that these natural products are interesting prototype compounds in the study of new antidepressant drugs. So, this review will summarize the chemical and pharmacological perspectives related to the discovery of flavonoids with antidepressant activity. The mechanisms of action of these compounds are also discussed, including their actions on oxidative stress relating to depression.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29410733 PMCID: PMC5749298 DOI: 10.1155/2017/5762172
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Flavonoids studied in experimental depression.
| Flavonoid | Administration | Animal species | Depression model | Observed effects | Mechanism of action | Observation | Reference |
|---|---|---|---|---|---|---|---|
|
| Oral | Rat | FST | Reduced immobility time | Attenuated hyperglycaemia | DR+ | [ |
| Oral | Mice | TST, OFT | No effects | Increased the 5-HT and DA levels in the CNS | DR+ | [ | |
| Intraperitoneal, acute, and chronic | Mice | TST, OFT | Reduced immobility time | Increased the BDNF levels in the hippocampus | DR+ | [ | |
| Intraperitoneal | Mice | TST, FST, and OFT | Reduced immobility time | Interaction with the serotonergic system (5-HT1A receptors) | DR+ | [ | |
| Intraperitoneal | Mice | FST, OFT | Reduced immobility time | Interaction with the | DR+ | [ | |
| Oral | ICR mice | CMS, FST | Reduced immobility time | Reversed the reduction of sucrose preference. | DR+ | [ | |
|
| Oral | Mice | CUMS, SPT, OFT, and FST | Reduced immobility time | Increased the sucrose preference | DR+ | [ |
| Oral | Mice | ST, OFT, and FST | Reduced immobility time | Increased BDNF levels | DR+ | [ | |
| Oral | Mice | ST, rota rod, and TST | Reduced immobility time | Decreased 5-HT levels in the hippocampus | DR+ | [ | |
|
| Oral | ICR mice | OFT, TST | Reduced immobility time | Increased 5-HT and norepinephrine and GR levels | DR+ | [ |
| Oral | ICR mice | CUMS, SPT, and NSFT | Enhanced the BDNF expression in the hippocampus but not in the frontal cortex | DR+ | [ | ||
|
| Intraperitonial | Mice | CUMS, OFT, FST, TST, and SPT | Reduced immobility time | Upregulation of monoaminergic neurotransmitters (5-HT and DA) | DR+ | [ |
|
| Oral | Rat | SPT, CMS, and FST | Reduced immobility time | Attenuated oxidative stress damage and neuroinflammation | DR+ | [ |
| Oral | Mice | Social defeat | Attenuated the increases in serum IL-6 and TNF- | DR+ | [ | ||
| Oral | Rat | SPT | Attenuated the development of depression-like behaviors | DR+ | [ | ||
|
| Oral | Mice | FST, TST | Reduced immobility time | Acts as a TrkB receptor-specific agonist | [ | |
|
|
| PC12 cell line | Evaluation of cell viability | Protected PC12 cells from the lesion induced by corticosterone | DR+ | [ | |
| Intraperitonial | Mice | FST | Reduced motor activity | Activation of D2-DA receptors | DR+ | [ | |
|
| Oral | Rat | CMS | Reduced immobility time | Decreased the activity and expression COX-2 | DR+ | [ |
| Intraperitonial | Mice/ rat | OFT, FST, and TST | Reduced immobility time | Reversed the reduction of extracellular ERKs phosphorylation | DR+ | [ | |
|
| Subcutaneous | Mice | FST, TST | Reduced immobility time | Attenuated corticosterone-induced depressive-like behavior | [ | |
|
| Oral | Mice | FST, TST, and OFT | Reduced immobility time | Interaction with presynaptic 5-HT1A receptors (serotonergic neurotransmitter system) | DR+ | [ |
|
| Oral | Mice | TST, OFT | No effects | Increased the 5-HT and DA levels in the CNS | DR+ | [ |
|
| Oral | ICR mice | FST, TST | Reduced immobility time | Attenuated the expression of endoplasmic reticulum stress-related proteins in the hippocampus | [ | |
| Oral | ICR Mice | FST, OFT | Reduced immobility time | Potentiation the GABAA receptor-Cl− ion channel complex | DR+ | [ | |
|
| Oral | Mice | MFTS, TST, and plus-maze | Reduced immobility time | Increased the catecholamine levels in the synaptic cleft | DR+ | [ |
|
| Oral | Mice | FTS, TST | Reduced immobility time | Interaction with serotonergic (5-HT2 receptors) and noradrenergic systems ( | DR+ | [ |
|
| Oral | Mouse | FST, TST | Reduced immobility time | Regulation of the central 5-HT in and NE, levels (inhibition of MAO activity) | DR+ | [ |
| Oral | Mice | FST, TST | Reduced immobility time | Antagonized iNOS mRNA expression and nitrite levels via the modulation of NF- | DR+ | [ | |
|
| Oral | Mice | FST, TST | Reduced immobility time | Interaction with the serotonergic, noradrenergic and dopaminergic systems | DR+ | [ |
|
| Intraperitonial | Rat | FST | Reduced immobility time | Attenuated depressive-like behaviours | DR+ | [ |
| Oral | Rat | Acute stress, EPM | No effects | Protective effects on stress exposure | DR+ | [ | |
| Oral | Rat | OFT | Reduced immobility time | Neuroprotective effects | DR+ | [ |
FST: forced swimming test; CNS: central nervous system; EPM: elevated plus maze; SPT: sucrose preference test; BDNF: brain-derived neurotrophic factor; CMS: chronic mild stress; NGF: nerve growth factor; ERK: extracellular signal-related kinase; ST: splash test; MFTS: modified forced swimming test; NSFT: novelty-suppressed feeding test; NLRP3: nod-like receptor protein 3; TST: tail suspension test; GR: glucocorticoid receptor; OFT: open field test; CUMS: chronic unpredictable mild stress; DR+: dose/concentration response design; 5-HT: serotonin; DA: dopamine; NE: noradrenaline.
Figure 1Possible mechanism of action of flavonoids with antidepressant activity.